Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy.
Identifieur interne : 001139 ( Ncbi/Merge ); précédent : 001138; suivant : 001140Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy.
Auteurs : Mark H. Yudin [Canada]Source :
- Expert review of respiratory medicine [ 1747-6356 ] ; 2011.
Descripteurs français
- KwdFr :
- Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Complications de la grossesse et maladies infectieuses (), Complications de la grossesse et maladies infectieuses (traitement médicamenteux), Complications de la grossesse et maladies infectieuses (virologie), Facteurs de risque, Femelle, Grossesse, Humains, Résultat thérapeutique, Vaccins antigrippaux, Évaluation des risques.
- MESH :
- effets indésirables : Antiviraux.
- traitement médicamenteux : Complications de la grossesse et maladies infectieuses.
- usage thérapeutique : Antiviraux.
- virologie : Complications de la grossesse et maladies infectieuses.
- Complications de la grossesse et maladies infectieuses, Facteurs de risque, Femelle, Grossesse, Humains, Résultat thérapeutique, Vaccins antigrippaux, Évaluation des risques.
English descriptors
- KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Female, Humans, Influenza Vaccines, Pregnancy, Pregnancy Complications, Infectious (drug therapy), Pregnancy Complications, Infectious (prevention & control), Pregnancy Complications, Infectious (virology), Risk Assessment, Risk Factors, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : Pregnancy Complications, Infectious.
- prevention & control : Pregnancy Complications, Infectious.
- virology : Pregnancy Complications, Infectious.
- Female, Humans, Influenza Vaccines, Pregnancy, Risk Assessment, Risk Factors, Treatment Outcome.
Abstract
Pregnant women are particularly susceptible to influenza-related morbidity and mortality and have historically been over-represented among patients with influenza, requiring hospitalization and intensive care unit admission. This has been observed during both nonpandemic and pandemic influenza seasons. During the H1N1 influenza pandemic of 2009-2010, pregnant women again had an increased likelihood of hospital or intensive care unit admission, and many deaths were documented. One identified risk factor for more severe disease was a delay in the initiation of antiviral medications. Vaccination is currently the most effective method for preventing severe influenza and its sequelae, and antiviral medications are used as an important adjunct to vaccination. Knowledge among pregnant women regarding influenza vaccine recommendations is poor, but by improving knowledge and understanding, vaccine rates can be increased. Although there are no published data examining knowledge regarding antiviral medications, one can hypothesize that knowledge is similarly low. In the current era, the appropriate use of vaccination and antiviral medications is the best defense against complications of influenza among pregnant women, and optimizing knowledge about these strategies among providers and patients alike is of paramount importance.
DOI: 10.1586/ers.11.37
PubMed: 21859269
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F25
- to stream PubMed, to step Curation: 000F25
- to stream PubMed, to step Checkpoint: 000F04
Links to Exploration step
pubmed:21859269Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy.</title><author><name sortKey="Yudin, Mark H" sort="Yudin, Mark H" uniqKey="Yudin M" first="Mark H" last="Yudin">Mark H. Yudin</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada. yudinm@smh.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Obstetrics and Gynecology, St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21859269</idno><idno type="pmid">21859269</idno><idno type="doi">10.1586/ers.11.37</idno><idno type="wicri:Area/PubMed/Corpus">000F25</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F25</idno><idno type="wicri:Area/PubMed/Curation">000F25</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F25</idno><idno type="wicri:Area/PubMed/Checkpoint">000F04</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F04</idno><idno type="wicri:Area/Ncbi/Merge">001139</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy.</title><author><name sortKey="Yudin, Mark H" sort="Yudin, Mark H" uniqKey="Yudin M" first="Mark H" last="Yudin">Mark H. Yudin</name><affiliation wicri:level="4"><nlm:affiliation>Department of Obstetrics and Gynecology, St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada. yudinm@smh.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Obstetrics and Gynecology, St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><series><title level="j">Expert review of respiratory medicine</title><idno type="eISSN">1747-6356</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Influenza Vaccines</term><term>Pregnancy</term><term>Pregnancy Complications, Infectious (drug therapy)</term><term>Pregnancy Complications, Infectious (prevention & control)</term><term>Pregnancy Complications, Infectious (virology)</term><term>Risk Assessment</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Complications de la grossesse et maladies infectieuses ()</term><term>Complications de la grossesse et maladies infectieuses (traitement médicamenteux)</term><term>Complications de la grossesse et maladies infectieuses (virologie)</term><term>Facteurs de risque</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Résultat thérapeutique</term><term>Vaccins antigrippaux</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Complications de la grossesse et maladies infectieuses</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Complications de la grossesse et maladies infectieuses</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Influenza Vaccines</term><term>Pregnancy</term><term>Risk Assessment</term><term>Risk Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Complications de la grossesse et maladies infectieuses</term><term>Facteurs de risque</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Résultat thérapeutique</term><term>Vaccins antigrippaux</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pregnant women are particularly susceptible to influenza-related morbidity and mortality and have historically been over-represented among patients with influenza, requiring hospitalization and intensive care unit admission. This has been observed during both nonpandemic and pandemic influenza seasons. During the H1N1 influenza pandemic of 2009-2010, pregnant women again had an increased likelihood of hospital or intensive care unit admission, and many deaths were documented. One identified risk factor for more severe disease was a delay in the initiation of antiviral medications. Vaccination is currently the most effective method for preventing severe influenza and its sequelae, and antiviral medications are used as an important adjunct to vaccination. Knowledge among pregnant women regarding influenza vaccine recommendations is poor, but by improving knowledge and understanding, vaccine rates can be increased. Although there are no published data examining knowledge regarding antiviral medications, one can hypothesize that knowledge is similarly low. In the current era, the appropriate use of vaccination and antiviral medications is the best defense against complications of influenza among pregnant women, and optimizing knowledge about these strategies among providers and patients alike is of paramount importance.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21859269</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1747-6356</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Expert review of respiratory medicine</Title><ISOAbbreviation>Expert Rev Respir Med</ISOAbbreviation></Journal><ArticleTitle>Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy.</ArticleTitle><Pagination><MedlinePgn>495-501</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/ers.11.37</ELocationID><Abstract><AbstractText>Pregnant women are particularly susceptible to influenza-related morbidity and mortality and have historically been over-represented among patients with influenza, requiring hospitalization and intensive care unit admission. This has been observed during both nonpandemic and pandemic influenza seasons. During the H1N1 influenza pandemic of 2009-2010, pregnant women again had an increased likelihood of hospital or intensive care unit admission, and many deaths were documented. One identified risk factor for more severe disease was a delay in the initiation of antiviral medications. Vaccination is currently the most effective method for preventing severe influenza and its sequelae, and antiviral medications are used as an important adjunct to vaccination. Knowledge among pregnant women regarding influenza vaccine recommendations is poor, but by improving knowledge and understanding, vaccine rates can be increased. Although there are no published data examining knowledge regarding antiviral medications, one can hypothesize that knowledge is similarly low. In the current era, the appropriate use of vaccination and antiviral medications is the best defense against complications of influenza among pregnant women, and optimizing knowledge about these strategies among providers and patients alike is of paramount importance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yudin</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, St Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada. yudinm@smh.ca</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Respir Med</MedlineTA><NlmUniqueID>101278196</NlmUniqueID><ISSNLinking>1747-6348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21859269</ArticleId><ArticleId IdType="doi">10.1586/ers.11.37</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Yudin, Mark H" sort="Yudin, Mark H" uniqKey="Yudin M" first="Mark H" last="Yudin">Mark H. Yudin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001139 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001139 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:21859269
|texte= Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:21859269" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |